Malaysia Health Minister says new generics must not be delayed by interpretation of legislation
Malaysia does not want the introduction of new generic drugs to be obstructed and delayed by conflicting interpretations of national legislation and regulations on Trade-related Aspects of Intellectual Property Rights (TRIPS) by various parties, reports Bernama, the Malaysian national news agency.
Health Minister Datuk Seri Liow Tiong Lai said with the increasing number of patients with non-communicable diseases (NCDs), many countries were faced with a huge challenge in providing sufficient access to essential medicines to treat such cases.
“The positive economic impact of generic substitutions can be enormous. For Malaysia which provides free medical care to its citizens, generics are essential to meet the continuous delivery of health care to its population,” he said in his speech at the United Nations High-Level Meeting on NCDs in New York on Monday.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze